About Array Biopharma
Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The company is building a fully integrated, commercial-stage biopharmaceutical company that discovers, develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer.
Array Biopharma Patents
Array Biopharma has filed 250 patents.
Latest Array Biopharma News
Jun 5, 2023
Dilated Cardiomyopathy Market is Growing Rapidly with Value of USD 450 million by 2029 Dilated Cardiomyopathy market report gives details about historic data, present market trends, future product environment, marketing strategies, technological innovation, upcoming technologies, emerging trends or opportunities, and the technical progress in the related industry in this market research report. The report provides market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, their preferences for particular product and market demand and supply scenarios. For sound decision making and superior management of goods and services, these days businesses are adopting a market research report solution. An influential Dilated Cardiomyopathy market report is mainly delivered to the users in the form of PDF or spreadsheet. However, PPT format can also be offered if the client has specified such requirement. The competitive landscape part of the report provides a clear insight into the market share analysis of key industry players. CAGR values for the market for an estimated forecast period of 2022 to 2029 are mentioned in the report which helps determine costing and investment values or strategies. By combining lot of efforts and leaving no stone unturned, this market report has been prepared. In addition, Dilated Cardiomyopathy market document also offers top to bottom assessment of the market as far as income and developing business sector is concerned. Data Bridge Market Research analyses a growth rate in the global dilated cardiomyopathy market in the forecast period 2022-2029. The expected CAGR of global dilated cardiomyopathy market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 328.8 million in 2021, and it would grow upto USD 450 million by 2029. The global dilated cardiomyopathy market is tend to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. Some of The Major Companies That Are Covered In This Report: Alexion Pharmaceuticals, Inc. (U.S.) Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-dilated-cardiomyopathy-market Dilated cardiomyopathy is a term given to the heart muscle diseases and is considered a fatal cardiac disorder. It is usually typically characterised by left and right ventricular dilation and reduced myocardial contractility. A common cause of heart failure is the incompetence of the heart to supply the body with enough blood, and dilated cardiomyopathy also contributes to factors such as irregular heartbeats, blood clots, or sudden death. People of all age groups are affected by dilated cardiomyopathy, which includes infants and children, but it is most common in men ages 20 to 50. This diseased condition is increasing and thus it is very important to the healthcare sector. It offers cautious encounters on the current and past examples of the business which rely upon the events that have occurred around here space and data accumulated from them. The archive further assesses the current business patterns which are needy upon the past data. Also, it offers data on key conditions, for example, the COVID-19 pandemic and its impact on the extensive length and passing impact on the business space. Drivers Increase in Diagnostic Tests Different diagnostic tests used to treat peripartum cardiomyopathy market are boosting the market growth. Multiple tests such as electrocardiography, cardiac MRI to detect the presence of specific defects. Thus, it acts as a major driver in the market growth. According to WHO statistics for the year 2020, ischemic heart disease accounts for 16% of all fatalities globally. As per the February 2020 article titled “Heart failure (HF) in France: Chronic Heart Failure Therapeutic Management and Risk of Cardiac Decompensation in Real-Life Setting,” about 1 million people in France would be affected by heart failure. Despite well-defined treatment management, there are approximately 70,000 heart failure-related deaths and more than 150,000 hospitalizations. This boosts the market growth. Opportunities Increase in Smoking and Lifestyle Changes Cigarette smoking is one of the leading cause of preventable disease and death in the U.S. It accounts for more than 480,000 deaths every year. In addition to this, the lifestyle changes that are attained by today’s population such as unhealthy lifestyle, poor diet, stress and many such factors altogether contribute to the developing opportunities of the market. Increase in the number of research and development activities The market’s growth is boosted by an increase in the number of R&D activities. This will provide beneficial opportunities for the global dilated cardiomyopathy market. To motivate researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives. For instance, ARRY-371797, also known as ARRY-797, is an oral, p38 mitogen-activated protein kinase (MAPK) inhibitor discovered by Array scientists. It is under phase III trial for the treatment of patients suffering from dilated cardiomyopathy due to a Lamin A/C gene mutation. In 2019, Pfizer acquired Array Biopharma to expand its pipeline. This drug is in phase III pipeline drugs of Pfizer under the name PF-07265803 for treating patients affected by dilated cardiomyopathy. The geographic regions and countries covered in the study include: North America, South America, Asia and Pacific Region, Middle east and Africa and Europe. The Key Points of Global Dilated Cardiomyopathy Market – The Global Dilated Cardiomyopathy Market trend study is based upon the CAGR calculated between 2021 and 2028. It includes all information about the market’s top manufacturers, consumers, distributors, and key players. To study the industry’s performance within each region, we determine the Global Dilated Cardiomyopathy Market share as well as its growth rate. This Research report gives a significant wellspring of wise for business tacticians and serious examination of the worldwide market. Recent Developments: In August 2019, MyoKardia, Inc., launched the 2nd Annual Myoseeds Research Grant Program to promote independent biology research and understand the mechanism of cardiomyopathies and its associated treatment. In 2019, the DCM Foundation in Ohio announced the launch of a website to raise awareness for dilated cardiomyopathy (DCM) and educate the patients to manage the heart condition. Many causes of DCM have been reported and around 1 in 250 people have DCM. Most of the patients have been reported to suffer from Idiopathic DCM. Therefore, genetic factors are considered to play a major role in idiopathic DCM. Henceforth, in order to find this relation, DCM foundation has collaborated with DCM Research Project which is funded by National Institute of Health (NIH). Global Dilated Cardiomyopathy Market Scope The global peripartum cardiomyopathy market is segmented on the basis of drug class, treatment type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications. Drug class
Array Biopharma Frequently Asked Questions (FAQ)
When was Array Biopharma founded?
Array Biopharma was founded in 1998.
Where is Array Biopharma's headquarters?
Array Biopharma's headquarters is located at 3200 Walnut Street, Boulder.
What is Array Biopharma's latest funding round?
Array Biopharma's latest funding round is Acq - P2P.
How much did Array Biopharma raise?
Array Biopharma raised a total of $32.81M.
Who are the investors of Array Biopharma?
Investors of Array Biopharma include Pfizer, Boulder Ventures, Mitsui & Co. Global Investment, ARCH Venture Partners, Advent International and 6 more.
Who are Array Biopharma's competitors?
Competitors of Array Biopharma include Trellis Bioscience, Albireo Pharma, ChemoCentryx, Cerecin, Clarus Therapeutics, MaxCyte, Pfenex, Molmed, Portola Pharmaceuticals, AM-Pharma and 85 more.
Compare Array Biopharma to Competitors
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment. The company was founded in 2001 and is based in Singapore.
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.